中国暂停争议性临床试验
STAT+: A possible comeback for a failed sickle cell gene therapy
中国政府因新患者死亡事件对争议性临床试验实施了新的限制,导致研究速度放缓。这一举措可能令急于缩短开发时间的美国生物技术公司感到失望。
China hits the brakes on controversial trials, RevMed’s red-hot cancer drug launch, and more biotech news
![]()
![]()
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The news is newsing hard these days, no?
China hits the brakes on controversial trials
China’s fast, cheap route to human testing is getting considerably less speedy. New government restrictions and news of recent patient deaths have slowed investigator-initiated trials, or IITs, STAT’s Jason Mast reports. This is perhaps to the chagrin of U.S. biotechs eager to bypass lengthy development timelines.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Biotech Correspondent
Meghana Keshavan covers biotech and contributes to The Readout newsletter.
-
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
来源:STAT Pharma 医药频道 · statnews.com